Sarepta enters into long-term strategic manufacturing partnership with Brammer Bio
Sarepta Therapeutics announced it has entered into a long-term strategic manufacturing partnership with Brammer Bio, which will provide Sarepta access to clinical and commercial manufacturing capacity for its micro-dystrophin Duchenne muscular dystrophy gene therapy program. June 13, 2018